FY2027 Earnings Estimate for AXSM Issued By Leerink Partnrs

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Research analysts at Leerink Partnrs increased their FY2027 earnings per share (EPS) estimates for Axsome Therapeutics in a note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of $4.20 per share for the year, up from their previous forecast of $4.10. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share.

Several other research firms have also recently issued reports on AXSM. Cantor Fitzgerald reiterated an “overweight” rating and set a $153.00 target price on shares of Axsome Therapeutics in a research report on Wednesday, February 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $153.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, April 1st. Wells Fargo & Company boosted their target price on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Axsome Therapeutics in a research report on Tuesday, February 11th. They set a “buy” rating and a $176.00 target price for the company. Finally, Mizuho lifted their price target on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the company an “outperform” rating in a report on Thursday, March 27th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $169.80.

Axsome Therapeutics Stock Up 0.3 %

AXSM stock opened at $103.83 on Tuesday. The business’s 50-day moving average price is $119.19 and its 200-day moving average price is $102.18. The stock has a market cap of $5.06 billion, a P/E ratio of -17.33 and a beta of 0.88. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The firm had revenue of $118.77 million for the quarter, compared to analysts’ expectations of $117.83 million.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 22.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in Axsome Therapeutics by 14.9% in the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock valued at $19,062,000 after acquiring an additional 27,534 shares in the last quarter. Strategic Financial Concepts LLC acquired a new stake in shares of Axsome Therapeutics in the 4th quarter valued at $2,599,000. Intech Investment Management LLC lifted its position in shares of Axsome Therapeutics by 46.5% during the 4th quarter. Intech Investment Management LLC now owns 16,028 shares of the company’s stock worth $1,356,000 after purchasing an additional 5,087 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Axsome Therapeutics during the fourth quarter worth $14,771,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Axsome Therapeutics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company’s stock valued at $27,755,000 after buying an additional 5,438 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.